Fiche publication
Date publication
septembre 2024
Journal
Bulletin du cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Dr D'AVENI-PINEY Maud
Tous les auteurs :
Mediavilla C, D'Aveni M, Huynh A, Joris M, Masouridi-Levrat S, Nguyen S, Turlure P, Magro L, Guillaume T
Lien Pubmed
Résumé
Allogeneic hematopoietic stem cell transplantation (alloHSCT) is a potentially curative treatment for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). However, these transplants are complicated by a high rate of relapse in very high cytogenetic risk or refractory diseases. The benefit of this therapeutic strategy for these serious malignant hemopathies could therefore be reassessed. As part of the 14th workshop for the harmonization of allograft practices organized by the francophone society of bone marrow transplantation and cellular therapy (SFGM-TC) (SFGM-TC) in Lille in September 2023, the role of allograft for very high risk or refractory AML and MDS was challenged after analysis of published studies.
Mots clés
Allogreffe de cellules souches hématopoïétiques, Leucémie aiguë myéloblastique, Syndrome myélodysplasique, Very high-risk acute myeloid leukemia, Very high-risk myelodysplastic syndrome
Référence
Bull Cancer. 2024 09 5;:
